Recursion Pharmaceuticals Stock Current Valuation
| RXRX Stock | USD 5.89 0.11 1.83% |
Valuation analysis of Recursion Pharmaceuticals helps investors to measure Recursion Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to rise to about 1.9 B in 2024, whereas Enterprise Value Over EBITDA is likely to drop (5.99) in 2024. Fundamental drivers impacting Recursion Pharmaceuticals' valuation include:
Price Book 4.3654 | Enterprise Value 2 B | Enterprise Value Ebitda (5.31) | Price Sales 35.1299 | Enterprise Value Revenue 30.23 |
Overvalued
Today
Please note that Recursion Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Recursion Pharmaceuticals is based on 3 months time horizon. Increasing Recursion Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Recursion Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Recursion Stock. However, Recursion Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.89 | Real 5.32 | Target 16.83 | Hype 5.89 | Naive 5.29 |
The intrinsic value of Recursion Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Recursion Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Recursion Pharmaceuticals helps investors to forecast how Recursion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Recursion Pharmaceuticals more accurately as focusing exclusively on Recursion Pharmaceuticals' fundamentals will not take into account other important factors: Recursion Pharmaceuticals Company Current Valuation Analysis
Recursion Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Recursion Pharmaceuticals Current Valuation | 1.95 B |
Most of Recursion Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Recursion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Recursion Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Recursion Pharmaceuticals is extremely important. It helps to project a fair market value of Recursion Stock properly, considering its historical fundamentals such as Current Valuation. Since Recursion Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Recursion Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Recursion Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Recursion Current Valuation Historical Pattern
Today, most investors in Recursion Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Recursion Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Recursion Pharmaceuticals current valuation as a starting point in their analysis.
Recursion Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Recursion Pharmaceuticals has a Current Valuation of 1.95 B. This is 86.4% lower than that of the Biotechnology sector and 57.96% lower than that of the Health Care industry. The current valuation for all United States stocks is 88.25% higher than that of the company.
Recursion Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Recursion Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics of similar companies.Recursion Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Recursion Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Recursion Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Recursion Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Recursion Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (3.77) % | ||||
| Current Valuation | 1.95 B | ||||
| Shares Outstanding | 381.74 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 68.90 % | ||||
| Number Of Shares Shorted | 62.43 M | ||||
| Price To Book | 4.37 X | ||||
| Price To Sales | 35.13 X | ||||
| Revenue | 44.58 M | ||||
| Gross Profit | (164.13 M) | ||||
| EBITDA | (299.57 M) | ||||
| Net Income | (328.07 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 50.67 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 1.83 X | ||||
| Cash Flow From Operations | (287.78 M) | ||||
| Short Ratio | 12.25 X | ||||
| Earnings Per Share | (1.54) X | ||||
| Price To Earnings To Growth | (0.60) X | ||||
| Target Price | 9.86 | ||||
| Number Of Employees | 500 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 2.29 B | ||||
| Total Asset | 653.7 M | ||||
| Retained Earnings | (967.62 M) | ||||
| Working Capital | 344.97 M | ||||
| Net Asset | 653.7 M |
About Recursion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Recursion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.